To access this element change to forms mode OFF
Grant Award View - GA204241
Targeting a novel epigenetic regulator of Hodgkin lymphoma, H2A.B, for...
GA ID:
GA204241
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
3-Nov-2021
Publish Date:
6-Dec-2021
Category:
Medical Research
Grant Term:
1-Jan-2022 to 31-Dec-2025
Value (AUD):
$1,041,340.60
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 20/21 1.1 Health and Medical Research
Grant Program:
Ideas Grants
Grant Activity:
Targeting a novel epigenetic regulator of Hodgkin lymphoma, H2A.B, for treament of cancer
Purpose:
We have identified a novel key regulator of Hodgkin Lymphoma, epigenetic factor, histone H2A.B. This proposal aims to develop novel therapeutic tools that would target H2A.B and potentially provide a more specific and less toxic treatment for Hodgkin Lymphoma patients. We will use Modular Nanotransporters, a highly specific intracellular delivery system, to target H2A.B for degradation and we will use the small molecule kinase inhibitors for functional inactivation of H2A.B.
GO ID:
GO Title:
2021 Ideas Grants
Internal Reference ID:
2021/GNT2010992
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
Australian National University
Recipient ABN:
52 234 063 906
Grant Recipient Location
Suburb:
Canberra City
Town/City:
Canberra City
Postcode:
2601
State/Territory:
ACT
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
ACT, Overseas
Postcode:
Multiple
Country:
AUSTRALIA, RUSSIAN FEDERATION